Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin detemir - Novo Nordisk

Drug Profile

Insulin detemir - Novo Nordisk

Alternative Names: Levemir; Levemir FlexPen; Levemir FlexTouch; LysB29-tetradecanoyl des-(B30) human insulin; NN 304

Latest Information Update: 13 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Aug 2017 Novo Nordisk terminates a phase III trial in Type-2 diabetes mellitus (In children, In adolescents, Adjunctive treatment) in USA, Brazil, Mexico, Germany, India, Israel, South Korea, Malaysia, Russia, Taiwan, Turkey, Portugal, Hungary, Croatia, Greece and Spain (SC) (NCT02131272)
  • 01 Jun 2016 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus (In children, In adolescents, Adjunctive treatment) in USA, Brazil, Germany, Hungary, India, Israel, South Korea, Malaysia, Mexico, Russia, Taiwan and Turkey (NCT02131272)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top